Medpace Holdings Inc (MEDP)
NASDAQ:MEDP
Want to see MEDP full AI Analyst Report?
Top Page
Medpace Holdings
(NASDAQ:MEDP)
Select Model
Select Model
Rating:72Outperform
Price Target:
$467.00
▼(-10.30% Downside)
Action:Reiterated
Date:05/20/26
The score is led by strong financial performance (profitability and very strong free cash flow), partially offset by weak technical trends (price below key moving averages and negative MACD). Earnings-call takeaways are mixed—guidance was reaffirmed and results were strong, but cancellations and weakening longer-dated backlog coverage increase growth uncertainty. Valuation is reasonable but not cheap and lacks dividend support.
Positive Factors
Free Cash Flow Strength
Very strong and consistent free cash flow generation provides durable financial flexibility. High FCF and near-1.0 conversion to net income supports reinvestment, working-capital needs, debt servicing and optional capital returns or M&A, cushioning the firm through multi-quarter revenue variability.
Negative Factors
Booking Weakness / Book-to-Bill
Net book-to-bill below 1.0 signals that cancellations and softer gross bookings are outpacing new awards, which can compress future revenue growth. If sustained, this reduces forward revenue visibility, pressures capacity utilization and requires stronger win rates to stabilize topline momentum.
Read all positive and negative factors
Positive Factors
Negative Factors
Free Cash Flow Strength
Very strong and consistent free cash flow generation provides durable financial flexibility. High FCF and near-1.0 conversion to net income supports reinvestment, working-capital needs, debt servicing and optional capital returns or M&A, cushioning the firm through multi-quarter revenue variability.
Read all positive factors
Medpace Holdings Key Performance Indicators (KPIs)
Medpace Holdings (MEDP) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.77B
Dividend YieldN/A
Average Volume (3M)442.19K
Price to Earnings (P/E)27.6
Beta (1Y)1.18
Revenue Growth24.19%
EPS Growth20.19%
CountryUS
Employees5,900
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)16.24
Shares Outstanding28,559,689
10 Day Avg. Volume305,204
30 Day Avg. Volume442,187
Financial Highlights & Ratios
PEG Ratio1.82
Price to Book (P/B)35.29
Price to Sales (P/S)6.40
P/FCF Ratio23.76
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue4.58
Enterprise Value/Gross Profit15.75
Enterprise Value/Ebitda21.15
Forecast
1Y Price Target
$447.50Price Target Upside-14.04% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)16.99
Revenue Forecast (FY)$2.77B
Medpace Holdings Business Overview & Revenue Model
Company Description
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various ...
How the Company Makes Money
Medpace makes money by selling outsourced research and development services to life sciences sponsors, primarily for the conduct of clinical trials. Its revenue is generated through contracts with customers to perform clinical development work, wi...
Medpace Holdings Earnings Call Summary
Earnings Call Date:Apr 22, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Jul 27, 2026
Earnings Call Sentiment Neutral
The call showed strong underlying financial performance in Q1 — double-digit revenue and EBITDA growth, healthy cash generation, and a sizable backlog — and management reaffirmed full-year guidance. However, elevated and persistent cancellations, weaker gross bookings/RFPs and a multi-quarter decline in beyond-12-month backlog coverage are meaningful near- to medium-term risks to sequential growth. Management pointed to a good win rate and initiatives to improve pipeline conversion, but the cadence and durability of that improvement remain uncertain.Positive Updates
Strong Revenue Growth
Q1 2026 revenue of $706.6 million, up 26.5% year-over-year (25.8% constant currency).
Negative Updates
Elevated Cancellations and Book-to-Bill Pressure
Cancellations rose again in Q1 with backlog cancellations at their highest level in over a year; net book-to-bill fell to 0.88, reflecting a combination of higher cancellations and softer gross bookings.
Read all updates
Q1-2026 Updates
Positive
Negative
Strong Revenue Growth
Q1 2026 revenue of $706.6 million, up 26.5% year-over-year (25.8% constant currency).
Read all positive updates
Company Guidance
Management reconfirmed its 2026 guidance ranges for revenue, EBITDA, net income and EPS (unchanged from the prior quarter), assuming an effective tax rate of 19–20% and $27.5M of interest income, with no additional share repurchases in guidance; underlying Q1 results that support the outlook included revenue of $706.6M (+26.5% YoY; +25.8% constant currency), EBITDA $149.4M (+25.9%; +28.6% CC) with a 21.1% margin, net income $123.9M (+8.1%), diluted EPS $4.28, operating cash flow $151.8M, net new awards of $618.4M (net book‑to‑bill 0.88), ending backlog of ~$2.9B (+2.9% YoY) with ~$1.94B expected to convert to revenue in the next 12 months (Q1 backlog conversion 23.3%), cash of $652.7M, negative net DSO of 58.8 days, and top‑5/top‑10 customer concentration of roughly 28%/37% of LTM revenue.Medpace Holdings Financial Statement Overview
Summary
Income Statement
86
Very Positive
Balance Sheet
74
Positive
Cash Flow
88
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.68B | 2.53B | 2.11B | 1.89B | 1.46B | 1.14B |
| Gross Profit | 778.59M | 760.62M | 656.30M | 524.50M | 432.44M | 328.15M |
| EBITDA | 579.87M | 570.50M | 476.12M | 363.15M | 301.04M | 219.73M |
| Net Income | 460.40M | 451.12M | 404.39M | 282.81M | 245.37M | 181.85M |
Balance Sheet | ||||||
| Total Assets | 2.13B | 1.98B | 2.10B | 1.66B | 1.35B | 1.66B |
| Cash, Cash Equivalents and Short-Term Investments | 652.68M | 497.05M | 669.44M | 245.45M | 28.27M | 461.30M |
| Total Debt | 146.09M | 250.50M | 149.52M | 142.12M | 188.87M | 130.97M |
| Total Liabilities | 1.53B | 1.52B | 1.28B | 1.10B | 966.11M | 707.01M |
| Stockholders Equity | 598.31M | 459.07M | 825.54M | 558.95M | 386.39M | 952.93M |
Cash Flow | ||||||
| Free Cash Flow | 737.82M | 681.87M | 572.27M | 396.73M | 351.17M | 235.06M |
| Operating Cash Flow | 739.17M | 713.22M | 608.82M | 433.37M | 388.05M | 263.33M |
| Investing Cash Flow | -27.90M | -31.14M | -28.31M | -34.63M | -38.74M | -31.36M |
| Financing Cash Flow | -501.75M | -860.39M | -154.01M | -182.64M | -775.77M | -44.45M |
Medpace Holdings Technical Analysis
Negative
520.60
Price Trends
455.53
Negative
486.96
Negative
512.88
Negative
Market Momentum
-4.02
Negative
55.51
Neutral
81.04
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MEDP, the sentiment is Negative. The current price of 520.6 is above the 20-day moving average (MA) of 425.87, above the 50-day MA of 455.53, and above the 200-day MA of 512.88, indicating a neutral trend. The MACD of -4.02 indicates Negative momentum. The RSI at 55.51 is Neutral, neither overbought nor oversold. The STOCH value of 81.04 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MEDP.
Medpace Holdings Risk Analysis
Medpace Holdings disclosed 37 risk factors in its most recent earnings report. Medpace Holdings reported the most risks in the "Legal & Regulatory" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Medpace Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $12.77B | 27.62 | 120.89% | ― | 24.19% | 20.19% | |
72 Outperform | $44.45B | 41.21 | 70.87% | ― | 13.08% | 25.40% | |
65 Neutral | $10.42B | 47.15 | 2.44% | ― | -0.37% | -70.42% | |
63 Neutral | $11.66B | 48.54 | 3.28% | 0.29% | 4.79% | -16.36% | |
57 Neutral | $8.70B | -47.91 | -5.74% | ― | 0.11% | -492.25% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
MEDP
Medpace Holdings
447.11
149.30
50.13%
CRL
Charles River Labs
180.71
45.67
33.82%
ICLR
Icon
136.07
7.17
5.56%
IDXX
Idexx Laboratories
563.53
48.73
9.47%
RVTY
Revvity
104.55
15.49
17.39%
Medpace Holdings Corporate Events
Business Operations and StrategyRegulatory Filings and ComplianceShareholder Meetings
Medpace shareholders approve governance changes enhancing voting rights
Positive
May 19, 2026
At its May 15, 2026 annual meeting, Medpace Holdings, Inc. shareholders approved amendments to the company’s Restated Certificate of Incorporation to eliminate supermajority voting requirements and remove prior limits on stockholders’ ...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Medpace Announces Strong Q1 Results Amid Leadership Transition
Positive
Apr 22, 2026
Medpace Holdings reported that first-quarter 2026 revenue rose 26.5% year on year to $706.6 million, with GAAP net income increasing to $123.9 million and EBITDA up 25.9% to $149.4 million, supported by strong cash generation and a modestly expand...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.